Item 8.01. Other Events.

As previously disclosed by InVivo Therapeutics Holdings Corp. (the "Company") on that certain Current Report on Form 8-K filed on May 21, 2021, with the U.S. Securities and Exchange Commission (the "SEC"), on May 19, 2021, the Company received a written notice (the "Initial Notice") from the Listing Qualifications department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share of the Company's common stock (the "Minimum Bid Price Requirement"). The Initial Notice provided the Company 180 calendar days, or until November 15, 2021, to regain compliance with the Minimum Bid Price Requirement.

Further, as previously disclosed by the Company on that certain Current Report on Form 8-K filed on November 16, 2021 with the SEC, on November 16, 2021, the Company received a written notice from the Listing Qualifications department of Nasdaq that the Company had been granted an additional 180 calendar days, or until May 16, 2022, to regain compliance with the Minimum Bid Price Requirement.

On May 11, 2022, the Company received a letter (the "Compliance Letter") from the Listing Qualifications department of Nasdaq notifying the Company that it has regained compliance with the Minimum Bid Price Requirement. The Compliance Letter noted that (i) the Company's common stock had a closing bid price of at least $1.00 for ten consecutive trading days from April 26, 2022, to May 10, 2022, and (ii) the Company has regained compliance with the Minimum Bid Price Requirement. Accordingly, Nasdaq considers the matter closed.

© Edgar Online, source Glimpses